Elan Beats Investor Fraud Claims Over Drug Prospects

Law360, New York (August 10, 2011, 7:30 PM ET) -- A New York federal judge on Tuesday tossed two class actions alleging that Elan Corp. PLC misled investors about the prospects for two of its drugs, one a possible treatment for Alzheimer's disease.

U.S. District Judge Alvin Hellerstein reviewed the plaintiffs’ brief in favor of once more amending their complaints but concluded that the additional allegations did nothing to cure fatal deficiencies he pointed out at a hearing in June.

“These new allegations may offer additional details regarding plaintiffs' theory of their cases, but they do...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

In re ELAN CORPORATION SECURITIES LITIGATION


Case Number

1:08-cv-08761

Court

New York Southern

Nature of Suit

Securities/Commodities

Judge

Alvin K. Hellerstein

Date Filed

October 14, 2008


Case Title

Kleiman v. Elan Corporation, PLC et al


Case Number

1:10-cv-05630

Court

New York Southern

Nature of Suit

Securities/Commodities

Judge

Alvin K. Hellerstein

Date Filed

July 23, 2010

Law Firms

Companies

Government Agencies